


IDS Form PTO/SB/08: Substitute for form 1449A/PTO				<b>Complete if Known</b> 	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				Application Number	10/519,162
				Filing Date	December 23, 2004
				First Named Inventor	Kazuo UMEZAWA
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	3	Attorney Docket Number	09707.0001


U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. <sup>1</sup>	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
		4,861,872	08-29-1989	Okamoto et al.	
		4,912,205	03-27-1990	Okamoto et al.	

**Note: Copies of the U.S. Patent Documents are not Required in IDS filed after October 21, 2004**

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
		WO 00/02548	01-20-2000	Osteoscreen		
		JP63-178101	07-22-1988	Daicel Chem Ind. Ltd.		abstract
		JP6-211902	08-02-1994	Daicel Chem Ind. Ltd.		yes
		JP2001-296288	10-26-2001	Daicel Chem Ind. Ltd.		yes
		JP2001-352986	12-25-2001	Kyowa Hakko Kogyo Co. Ltd		yes
		JP2002-128690	05-09-2002	Hirohata Tashinari		yes

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation <sup>6</sup>
		KOBAYASHI M., "Expression Regulation of TNF $\alpha$ in Adipocytes and Significance of Insulin Resistance", Igaku no ayumi, 184(6), pp. 562-66, (1998).	yes
		SCHDEL et al., "Synthesis of (R)-4,4,4-trifluoro-2-mercaptobutyric acid", Tetrahedron: Asymmetry, 11, pp. 2125-317, (2000).	
		KURU et al., "TNF Expression in Muscular Disorder", Neuroimmunology 10, pp. 174-75 (2002).	yes
		NAKAMURA et al., "Inhibitory Effect of New NF- $\kappa$ B Inhibitor DHME2Q for Human Breast Cancer Cells", Proceedings of the Japanese Cancer Association, 61 <sup>st</sup> Annual Meeting, Abstract 3550, p. 157 (2002).	yes
		HORIGUCHI et al., "Antitumor Effect of a Novel Nuclear Factor- $\kappa$ B Activation Inhibitor in Bladder cancer Cells, Expert Rev. Anticancer Ther. 3, pp. 793-8 (2003).	
		CHAICHARONPONG et al., "Preparation of Radioactively Labeled Dehydroxymethylepoxyquinomicin, an NF- $\kappa$ B Function Inhibitor", Drugs Exptl. Clin. Res. XXIX, pp. 1-3 (2003).	
		MIYAJIMA et al., "Novel Nuclear Factor $\kappa$ B Activation Inhibitor Prevents Inflammatory Injury in Unilateral Ureteral Obstruction", J. Urology 169, pp. 1559-63 (2003).	
		LIN et al., "(-)-Epigallocatechin-3-gallate Blocks the Induction of Nitric Oxide Synthase by Down-Regulating Lipopolysaccharide-Induced Activity of Transcription Factor Nuclear Factor- $\kappa$ B", Molecular Pharmacology 52, pp. 465-72 (1997).	


ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.P./

IDS Form PTO/SB/08: Substitute for form 1449A/PTO		<b>Complete if Known</b> 	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/519,162
		Filing Date	December 23, 2004
		First Named Inventor	Kazuo UMEZAWA
		Art Unit	Not Yet Assigned
		Examiner Name	Not Yet Assigned
Sheet	2	of	3
		Attorney Docket Number	09707.0001

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation <sup>6</sup>
		OHLSSON et al., "Oxidized Low Density Lipoprotein Inhibits Lipopolysaccharide-induced Binding of Nuclear Factor-κB to DNA and the Subsequent Expression of Tumor Necrosis Factor-α and Interleukin-1b in Macrophages, J. Clin. Invest. 98, pp. 78-89 (1996).	
		ELIGINI et al., "Oxidized Phospholipids Inhibit Cyclooxygenase-2 in Human Macrophages Via Nuclear Factor-κB/IKB and ERK-2-dependent Mechanisms", Cardiovascular Res. 55, pp. 406-15 (2002).	
		ARIGA et al., Seikagaku, Journal of Japanese Biochemical Society, 73(8) Abstract (2001).	yes
		UMEZAWA K., "New Molecular Targets of Antidiabetic Agents and Anticancer Agents and Inhibitors", The 2 <sup>nd</sup> Annual Report of the Center for the Development of Molecular Target Drugs, Symposium on Molecular Target Drugs in Kanazawa, Abstract (2002).	yes
		UMEZAWA K., "Role of Signal Transduction Inhibitors of Low Molecular Weight in Regenerative and Genetic Medicine", The 7 <sup>th</sup> Annual Scientific Meeting of Conference of Gene Therapy and Molecular Medicine, Abstract (2003).	yes
		ARIGA et al., "Synthesis of Novel Epoxydone Compound DHM2EQ and Its Suppression of NF-κB Action", The 4 <sup>th</sup> Annual Meeting of the Japanese Association for Molecular Target Therapy of Cancer, Abstract (2000).	yes
		SHIMA et al., "Inhibition of NF-κB Inhibitor DHMEQ of Adhesion Molecule Expression in vascular Cells", The 6 <sup>th</sup> Annual Meeting of the Japanese Association for Molecular Target Therapy of Cancer, Abstract (2002).	yes
		WATANABE et al., "Basic Studies of the Molecular Target Therapy of ATL Using Novel NF-κB Inhibitor", The 6 <sup>th</sup> Annual Meeting of the Japanese Association for Molecular Target Therapy of Cancer, Abstract (2002).	yes
		TAKAHASHI et al., "NF-κB Inhibition in Prostate Cancer Cells and Anti-Cancer Activity by DHMEQ", The 7 <sup>th</sup> Annual Meeting of the Japanese Association for Molecular Target Therapy of Cancer, Abstract (2003).	yes
		WATANABE et al., "Basic Studies of the Molecular Target Therapy of ATL Using Novel NF-κB Inhibitor", The 7 <sup>th</sup> Annual Meeting of the Japanese Association for Molecular Target Therapy of Cancer, Abstract S3-4 (2003).	yes
		TATETSU et al., "In Vivo and in Vitro Studies of Novel NF-κB Inhibitor (DHMEQ) in Myeloma Cells", The 28th Annual Meeting of Japan Myeloma Study Group, Abstract (2003).	yes
		ARIGA et al., "Inhibition of NF-κB by a Novel Epoxydone Compound", The 59 <sup>th</sup> Annual Meeting, Abstract (2000).	yes
		KIKUCHI et al., "Apoptosis-Induction in Hormone-Refractory Prostate Cancer Using a Novel NF-κB Activation Inhibitor", Proceedings of the Japanese Cancer Association, The 60 <sup>th</sup> Annual Meeting, Abstract (2001).	yes
		SHIMA et al., "Inhibition of Adhesion Molecule Expression by a NF-κB Inhibitor DHMEQ in Vascular Endothelial Cells", Proceedings of the Japanese Cancer Association, The 61th Annual Meeting, Abstract (2002).	yes
		NAMEKAWA et al., "Inhibition of NF-κB Activity in Bladder Carcinoma Cells", Proceedings of the Japanese Cancer Association, The 61th Annual Meeting, Abstract (2002).	yes
		WATANABE et al., "Basic Studies of the Molecular Target Therapy of ATL Using a Novel NF-κB Inhibitor", Proceedings of the Japanese Cancer Association, The 61th Annual Meeting, Abstract, p 162 (3486), (2002).	yes
		MATSUMOTO et al., "NF-κB Inhibitor Enhances the Anti-Cancer Effect of TNF-α Treatment and Ionizing Radiation in P.53 Wild Pancreatic Cancer", Proceedings of the Japanese Cancer Association, The 62 <sup>nd</sup> Annual Meeting, Abstract, p. 160 (2073-OA), (2003).	yes
		HORIE et al., Basic Studies of the Molecular Target Therapy of ATL Using a Novel NF-κB Inhibitor", Proceedings of the Japanese Cancer Association, The 62 <sup>nd</sup> Annual Meeting, Abstract, p. 153 (2039-OA), (2003).	yes
		SUZUKI et al., "Inhibition of Macrophage Activation by the Novel NF-κB Inhibitor, Dehydroxymethylepoxyquinomicin", The 3 <sup>rd</sup> International Symposium on Natural Drugs, Naples, Abstract (2003).	
		ARIGA et al., "Molecular Design and Biological Activities of a New NF-κB Inhibitor, Dehydroxymethylepoxyquinomicin (DHMEQ)", Faculty of Science and Technology, Biology and Pathology, Keio University, Yokohama 223-0061, Japan, Abstract (2002).	
		UMEZAWA, "Molecular Design and Biological Activities of NF-κB and Protein-Tyrosine Phosphatase Inhibitors", Department of Applied Chemistry, Keio University, Ewha Woman's University Annual Symposium (Gosari) (2002).	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.P./

IDS Form PTO/SB/08: Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/519,162
		Filing Date	December 23, 2004
		First Named Inventor	Kazuo UMEZAWA
		Art Unit	Not Yet Assigned
		Examiner Name	Not Yet Assigned
Sheet	3	of	3
		Attorney Docket Number	09707.0001



NON PATENT LITERATURE DOCUMENTS			
		HORIGUCHI et al., "A Novel NF-kB Activation Inhibitor Mediated Apoptosis as a New Therapeutic Approach in Hormone-Refractory Prostate Cancer", American Urological Association Annual Meeting, Abstract (2002).	
		MIYAJIMA et al., "Nuclear Factor-Kappa B Activation Inhibitor Prevents Renal Tissue Damage In Unilateral Ureteral Obstruction", American Urological Association Annual Meeting, Abstract (2002).	
		HORIGUCHI et al., "Anti-Tumor Effect of a Novel NF-kB Activation Inhibitor in Bladder Cancer Cells", American Urological Association Annual Meeting, Abstract (2003).	
		UMEZAWA, "Molecular Design and Biological Activities of a New NF-kB Inhibitor, Dehydroxymethylepoxyquinomicin", The 5 <sup>th</sup> International Symposium on Molecular Medicine, Crete, Greece, Abstract (2002).	
		NAMEKAWA et al., "Suppression of Human Breast Carcinomas in Mice by a Novel NF-kB Inhibitor DHMEQ", The 76 <sup>th</sup> Annual Meeting of the Japanese Biochemical Society, Abstract .	
		SUZUKI et al., "Inhibition of Ligand-Induced Macrophage Activation by an NF-kB Inhibitors, DHMEQ", The 76 <sup>th</sup> Annual Meeting of the Japanese Biochemical Society, Abstract	
		KUBOTAL et al., "Application of an NF-kB Inhibitor to the Therapy of SLE", The 67 <sup>th</sup> Annual Scientific Meeting of the American College of Rheumatology, Abstract (2003).	
		HORIGUCHI et al., "Suppression of Hormone-Refractory Prostate Cancer by a Novel NF-kB Inhibitor in Nude Mice", Proceedings of the American Association for Cancer Research 93 <sup>rd</sup> Annual Meeting, Abstract 2163.	
		ARIGA et al., "Inhibition of TNF-Alpha-Induced NF-Kappa B Functions by a Synthetic Epoxyquinomicin Analogue", Proceedings of the American Association for Cancer Research 92 <sup>nd</sup> Annual Meeting, Abstract 2111.	
		KIKUCHI et al., "A Novel Nf-kB Activation Inhibitor-Mediated Apoptosis As a New Therapeutic Approach In Hormone-Refractory Prostate Cancer", The 47 <sup>th</sup> Annual Congress of the Japan Section of the International College of Surgeons, Abstract (2001).	

Examiner Signature	/Kyle Purdy/	Date Considered	08/22/2008
--------------------	--------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.P./